MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Bofanglutide

  • Home
  • Bofanglutide
Comparative Efficacy and Safety of Bofanglutide versus Semaglutide in Chinese Patients with Type 2 Diabetes: Insights from a Phase 2b Trial
Posted inDiabetes & Endocrinology news

Comparative Efficacy and Safety of Bofanglutide versus Semaglutide in Chinese Patients with Type 2 Diabetes: Insights from a Phase 2b Trial

Posted by By MedXY 08/26/2026
This phase 2b trial evaluates bofanglutide's efficacy and safety compared to semaglutide in Chinese patients with type 2 diabetes, showing notable HbA1c reductions and manageable gastrointestinal side effects.
Read More
  • MDADI Composite Score Thresholds for Efficient Screening of Swallowing Impairment in Head and Neck Cancer Patients
  • Clinical Impact of Sentinel Lymph Node Biopsy in Atypical Endometrial Hyperplasia: Insights from a Multicenter Cohort Study
  • Comparative Efficacy and Safety of Bofanglutide versus Semaglutide in Chinese Patients with Type 2 Diabetes: Insights from a Phase 2b Trial
  • Equivalence of Online and In-Person Care in Managing Atopic Dermatitis: Insights from a Large Randomized Trial
  • Defining a Quantitative Perfusion Threshold with SPY-PHI QP to Predict Mastectomy Skin Necrosis in Breast Reconstruction: Insights and Clinical Implications
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top